Kim Tae Yong, Kim Kyung Won, Jung Tae Sik, Kim Jung Min, Kim Sun Wook, Chung Ki-Wook, Kim Eun Young, Gong Gyungyub, Oh Young Lyun, Cho Soo Youn, Yi Ka Hee, Kim Won Bae, Park Do Joon, Chung Jae Hoon, Cho Bo Youn, Shong Young Kee
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Head Neck. 2007 Aug;29(8):765-72. doi: 10.1002/hed.20578.
Anaplastic thyroid carcinoma (ATC), although rare, is one of the most aggressive human cancers, and patients with ATC have extremely poor prognoses despite various therapeutic measures. We wished to determine the prognostic factors of survival and effect of treatment on survival rate in patients with ATC.
We retrospectively reviewed the medical records of the 121 patients (41 men and 80 women) diagnosed with ATC from January 1995 to June 2004 at 5 major referral centers in Korea.
Mean patient age at diagnosis was 64 +/- 11 years (range, 17-84 years). Of the 121 patients, 11 (9%) had intrathyroidal tumors, 69 (57%) had extrathyroidal tumors or lymph node involvement, 29 (24%) had distant metastases, and 12 had no data about staging (9%). The mean tumor diameter was 5.5 +/- 2.5 cm (range, 0.5-17.0 cm). At a median follow-up of 41 months (range, 26-122 months), 8 patients were alive. Median survival time was 5.1 months. The disease-specific survival rates were 42% at 6 months, 16% at 12 months, and 9% at 24 months. Sixteen patients (13%) received only supportive care, 25 (21%) received surgery alone, 20 (16%) received radiation treatment or chemotherapy without surgery, and 60 (50%) received surgery plus radiation treatment or chemotherapy. Multivariate analysis showed that age less than 60 years, tumor size less than 7 cm, and lesser extent of disease were independent predictors of lower disease-specific mortality.
Long-term survival is possible for ATC patients less than 60 years old and with small localized tumors. Although aggressive multimodal therapy, including surgery, radiation treatment, and chemotherapy, was not significantly associated with improved survival, we advocate aggressive multimodal therapy in selected ATC patients with good prognostic factors.
间变性甲状腺癌(ATC)虽罕见,但却是侵袭性最强的人类癌症之一,尽管采取了各种治疗措施,ATC患者的预后仍极差。我们希望确定ATC患者的生存预后因素以及治疗对生存率的影响。
我们回顾性分析了1995年1月至2004年6月期间在韩国5家主要转诊中心诊断为ATC的121例患者(41例男性和80例女性)的病历。
诊断时患者的平均年龄为64±11岁(范围17 - 84岁)。121例患者中,11例(9%)有甲状腺内肿瘤,69例(57%)有甲状腺外肿瘤或淋巴结受累,29例(24%)有远处转移,12例无分期数据(9%)。肿瘤平均直径为5.5±2.5厘米(范围0.5 - 17.0厘米)。中位随访41个月(范围26 - 122个月)时,8例患者存活。中位生存时间为5.1个月。疾病特异性生存率在6个月时为42%,12个月时为16%,24个月时为9%。16例患者(13%)仅接受支持治疗,25例(21%)仅接受手术,20例(16%)接受了无手术的放疗或化疗,60例(50%)接受了手术加放疗或化疗。多因素分析显示,年龄小于60岁、肿瘤大小小于7厘米以及疾病范围较小是疾病特异性死亡率较低的独立预测因素。
年龄小于60岁且肿瘤局限较小的ATC患者有可能长期存活。尽管包括手术、放疗和化疗在内的积极多模式治疗与生存率改善无显著相关性,但我们主张对具有良好预后因素的特定ATC患者进行积极的多模式治疗。